Zagociguat is under clinical development by Tisento Therapeutics and currently in Phase I for Vascular Dementias. According to GlobalData, Phase I drugs for Vascular Dementias does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Zagociguat LoA Report. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - Zagociguat in Vascular Dementias

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Zagociguat overview

Zagociguat (CY-6463, IW-6463) is under development for the treatment of mitochondrial encephalomyopathy, cognitive impairment associated with schizophrenia, lactic acidosis, central nervous system indications such as neuroinflammation, vascular dementia. The drug candidate is administered by oral route. It targets soluble guanylate cyclase (sGC). It was under devlopment for the treatment of stroke-like episodes (MELAS), schizophrenia and Alzheimer’s disease.

Tisento Therapeutics overview

Tisento Therapeutics engaged in developing medicines for treatment of unmet medical needs diseases. The company is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Zagociguat’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 12 April 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.